Keros Therapeutics Stock Performance
| KROS Stock | USD 53.84 0.30 0.55% |
On a scale of 0 to 100, Keros Therapeutics holds a performance score of 8. The company secures a Beta (Market Risk) of 1.47, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Keros Therapeutics will likely underperform. Please check Keros Therapeutics' potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Keros Therapeutics' current price movements will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Keros Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Keros Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.53 | Five Day Return (9.82) | Year To Date Return 26.19 | Ten Year Return 171.04 | All Time Return 171.04 |
1 | Keros stock gains after trial update | 09/03/2024 |
2 | Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc. | 09/13/2024 |
3 | 17,540 Shares in Keros Therapeutics, Inc. Purchased by Point72 DIFC Ltd - MarketBeat | 09/26/2024 |
4 | Keros Therapeutics, Inc. Given Average Recommendation of Buy by Analysts - MarketBeat | 10/04/2024 |
5 | Acquisition by Nussbaum Ran of 10000 shares of Keros Therapeutics at 46.31 subject to Rule 16b-3 | 10/07/2024 |
6 | Disposition of 875 shares by Jennifer Lachey of Keros Therapeutics at 54.54 subject to Rule 16b-3 | 10/10/2024 |
7 | Keros Therapeutics, Inc. Sees Significant Decline in Short Interest | 10/16/2024 |
8 | Disposition of tradable shares by Bienaime Jean Jacques of Keros Therapeutics subject to Rule 16b-3 | 10/28/2024 |
9 | Insider Trading | 11/01/2024 |
10 | Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition | 11/05/2024 |
11 | Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference | 11/06/2024 |
12 | Keros Therapeutics Third Quarter 2024 Earnings US1.41 loss per share | 11/08/2024 |
13 | We Think Keros Therapeutics Can Afford To Drive Business Growth | 11/20/2024 |
| Begin Period Cash Flow | 280.4 M |
Keros |
Keros Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,541 in Keros Therapeutics on August 24, 2024 and sell it today you would earn a total of 843.00 from holding Keros Therapeutics or generate 18.56% return on investment over 90 days. Keros Therapeutics is currently generating 0.3083% in daily expected returns and assumes 2.7833% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Keros, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Keros Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Keros Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Keros Therapeutics, and traders can use it to determine the average amount a Keros Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1108
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KROS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.78 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.31 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Keros Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Keros Therapeutics by adding it to a well-diversified portfolio.
Keros Therapeutics Fundamentals Growth
Keros Stock prices reflect investors' perceptions of the future prospects and financial health of Keros Therapeutics, and Keros Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Keros Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (151.18) % | ||||
| Current Valuation | 1.68 B | ||||
| Shares Outstanding | 40.51 M | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 3,369 X | ||||
| Revenue | 151 K | ||||
| Gross Profit | (87.27 M) | ||||
| EBITDA | (152.18 M) | ||||
| Net Income | (152.99 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 14.44 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 13.57 X | ||||
| Cash Flow From Operations | (124.51 M) | ||||
| Earnings Per Share | (5.22) X | ||||
| Market Capitalization | 2.19 B | ||||
| Total Asset | 370.02 M | ||||
| Retained Earnings | (381.43 M) | ||||
| Working Capital | 322.92 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
About Keros Therapeutics Performance
Assessing Keros Therapeutics' fundamental ratios provides investors with valuable insights into Keros Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Keros Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (218.58) | (207.65) | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.46) | (0.48) |
Things to note about Keros Therapeutics performance evaluation
Checking the ongoing alerts about Keros Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Keros Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 151 K. Net Loss for the year was (152.99 M) with loss before overhead, payroll, taxes, and interest of (87.27 M). | |
| Keros Therapeutics currently holds about 215.62 M in cash with (124.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.37. | |
| Keros Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: We Think Keros Therapeutics Can Afford To Drive Business Growth |
- Analyzing Keros Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Keros Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Keros Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Keros Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Keros Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Keros Therapeutics' stock. These opinions can provide insight into Keros Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.